Biotech
-
David Altshuler, geneticist who helped transform Vertex, to retire next year
Since becoming Vertex's top scientist in 2015, Altshuler has helped the company become an industry powerhouse. He’ll depart next year in a “planned transition.”
By Ben Fidler • Aug. 5, 2025 -
Let’s make a deal? Big Pharma execs express varying views on their M&A future
Pharma executives are keeping their eyes open for dealmaking opportunities as every company has its own battles to fight.
By Michael Gibney • Aug. 5, 2025 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
Retrieved from Vinay Prasad on May 08, 2025
Dr. Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office got embroiled in controversy over a Duchenne gene therapy.
By Ben Fidler • July 30, 2025 -
Biotech investing is down, but some VC firms are bucking the trend
Discipline is the name of the game after a glut of over-investing burst the biotech bubble.
By Alexandra Pecci • July 29, 2025 -
Could bispecifics unseat Keytruda from its oncology throne?
Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.
By Kelly Bilodeau • July 28, 2025 -
From the bench: Researchers make NIH-funded preclinical strides in mRNA and obesity
The studies are contributing preclinical advances for some of the world’s biggest blockbusters.
By Michael Gibney • July 25, 2025 -
Who is Dr. George Tidmarsh, the new director of CDER?
Despite past criticism of public health policies, Tidmarsh recently praised the FDA and said he’ll focus on boosting review efficiencies.
By Meagan Parrish and Michael Gibney • July 23, 2025 -
FDA invites more data from abroad — with a wary eye on China
The FDA approved four drugs last year without any U.S. trial participants, but has maintained a tougher stance on China, even as it grows into an R&D powerhouse.
By Amy Baxter • July 16, 2025 -
Biotech IPO momentum gained steam last year, but market ‘turmoil’ has slowed the train again
The IPO market is a mixed bag in 2025, with some signs of life but several headwinds keeping activity relatively low.
By Michael Gibney • July 15, 2025 -
Early measles drug R&D kicks into gear as U.S. records record outbreak
Several companies have announced preclinical efforts to develop the first-ever measles treatment.
By Meagan Parrish • July 11, 2025 -
First 90 Days
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
By Amy Baxter • July 9, 2025 -
Is biopharma dealmaking getting hot again?
With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.
By Michael Gibney • July 8, 2025 -
The MEK effect on cancer — a slow and steady approach to drug resistance
Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.
By Kelly Bilodeau • July 8, 2025 -
Can China sustain a surge in oncology drug innovation?
The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.
By Kelly Bilodeau • July 2, 2025 -
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
By Michael Gibney • July 1, 2025 -
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.
By Delilah Alvarado • June 26, 2025 -
Biopharma is on edge about NIH funding cuts and what the future holds for research
Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.
By Michael Gibney • June 26, 2025 -
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
By Amy Baxter • June 25, 2025 -
Q&A
How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
By Michael Gibney • June 24, 2025 -
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
By Michael Gibney • June 20, 2025 -
How a patient group tackled research diversity for one disease and triggered change for pharma
A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.
By Meagan Parrish • June 17, 2025 -
Can ‘reputational pull’ save biotech from pharma’s image problem?
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
By Michael Gibney • June 12, 2025 -
Pharma’s wins and losses in the budget bill
Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.
By Amy Baxter • June 11, 2025 -
The biggest obesity deals of 2025 so far
Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.
By Amy Baxter • June 9, 2025 -
With ADCs on the rise, drugmakers embrace a new oncology pillar
A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.
By Michael Gibney • June 6, 2025